Drug Price Trends for GNP MUCUS ER

Average Pharmacy Cost for GNP MUCUS ER

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
GNP MUCUS ER 600 MG TABLET	46122-0750-51	0.32454	EACH	2025-02-19
GNP MUCUS ER 600 MG TABLET	46122-0750-51	0.35297	EACH	2025-01-22
GNP MUCUS ER 600 MG TABLET	46122-0750-51	0.34521	EACH	2024-12-18
GNP MUCUS ER 600 MG TABLET	46122-0750-51	0.39928	EACH	2024-11-20
GNP MUCUS ER 600 MG TABLET	46122-0750-51	0.32011	EACH	2024-10-23
GNP MUCUS ER 600 MG TABLET	46122-0750-51	0.35791	EACH	2024-09-18
GNP MUCUS ER 600 MG TABLET	46122-0750-51	0.30672	EACH	2024-08-21

Market Analysis and Price Projections for Guaifenesin: A Comprehensive Overview

Introduction to Guaifenesin

Guaifenesin, an ether of glycerin and guaiacol, is a widely used expectorant that helps in thinning and loosening mucus in the airways, making it easier to cough up. It is a key ingredient in various cough and cold medications, including extended-release tablets like GNP MUCUS ER.

Market Size and Growth Projections

The global guaifenesin market is anticipated to experience significant growth in the coming years. Here are some key projections:

• Market Size: The global guaifenesin market is forecasted to reach USD 95 million by 2027, growing at a CAGR of around 3.1% from 2022 to 2027[1].
• Segment Growth: The cough treatment drug segment, which includes guaifenesin, is the fastest-growing segment, expected to grow with a CAGR of around 3.7% during the forecast period[1].

Market Segmentation

By Product

The guaifenesin market is segmented into various product forms, including:

• Tablets: Extended-release tablets like GNP MUCUS ER are popular for their sustained action.
• Dissolving Granules: Easy to consume, especially for pediatric and geriatric patients.
• Syrup: Liquid form, often preferred for children.
• Extended-Release Tablets: Designed for prolonged action, reducing the need for frequent dosing[1].

By Purity

Guaifenesin is available in different purity levels:

• Below 99%
• 99%
• Above 99% The purity level can affect the pricing and application of the drug[1].

By Application

Guaifenesin is used in various applications:

• Cough Treatment Drug: The most common use, helping to thin and loosen mucus.
• Chest Congestion Medication: Often combined with decongestants.
• Anesthetic: Less common, but used in some medical procedures.
• Others: Including muscle relaxant uses and other therapeutic applications[1].

By End-Use Industry

The primary end-use industries include:

• Multispecialty Hospitals
• Clinics
• Others: Such as pharmacies and retail stores[1].

Geographic Analysis

Regional Market Performance

• North America: This region is expected to be the fastest-growing market for guaifenesin, with a CAGR of around 4.5% during the forecast period. The high demand is driven by the flourishing pharmaceutical sector and advanced medical infrastructure[1].
• Asia-Pacific: This region is also expected to see significant growth, driven by the expanding patient population and rapid economic development in countries like India and China[4].

Market Drivers

Increasing Demand for Cough and Cold Medications

The COVID-19 pandemic and subsequent respiratory illnesses have led to a surge in demand for expectorants like guaifenesin. This trend is expected to continue as respiratory diseases remain a significant health concern globally[3].

Advancements in Healthcare Infrastructure

The robust advancement in hospital infrastructure and innovation in drug delivery and processing projects are boosting the growth prospects for guaifenesin[1].

Economic Factors

The Indian pharmaceutical sector, for example, is expected to reach USD 65 billion by 2024 and around USD 120-130 billion by 2030, indicating a strong economic drive for the market[1].

Challenges and Limitations

Availability of Substitutes and Potential Side Effects

One of the major challenges facing the guaifenesin market is the availability of substitute drugs and potential side effects associated with guaifenesin. However, its efficacy and widespread use continue to support its market position[1].

Price Projections and Economic Impact

Market Pricing

The pricing of guaifenesin products, including extended-release tablets like GNP MUCUS ER, is influenced by several factors including production costs, regulatory environments, and market demand.

• Cost Savings: Initiatives like the Medicare Drug Price Negotiation Program aim to reduce drug costs for consumers. While guaifenesin is not currently listed among the negotiated drugs, broader market trends could influence its pricing[2].

Economic Impact

The growth of the guaifenesin market contributes significantly to the overall pharmaceutical sector. For instance, the Indian pharmaceutical sector's projected growth to USD 120-130 billion by 2030 indicates a substantial economic impact[1].

Key Players and Market Concentration

The guaifenesin market includes several key players:

• Merck KGaA
• Perrigo Company plc
• Sun Pharmaceutical Industries Ltd
• Johnson & Johnson Private Limited
• Sanofi

These companies play a crucial role in the production and distribution of guaifenesin products, including extended-release tablets[3].

Illustrative Statistics

• Market Size: The expectorant drugs market, which includes guaifenesin, is expected to reach USD 100 million in 2024 and grow to USD 120 million by 2029 at a CAGR of 4.5%[3].
• Prevalence of Respiratory Diseases: In the U.S., 4.6% of adults reported being diagnosed with COPD, emphysema, or chronic bronchitis in 2022, highlighting the demand for expectorants like guaifenesin[3].

Quotes from Industry Experts

"The increasing prevalence of respiratory diseases and the COVID-19 pandemic have significantly boosted the demand for expectorants like guaifenesin. This trend is expected to continue as healthcare infrastructure and pharmaceutical innovation advance." - Industry Analyst, Mordor Intelligence[3].

Highlight: Impact of COVID-19

"The COVID-19 pandemic had a significant impact on the expectorant drugs market. The initial virus outbreak led to a surge in the demand for over-the-counter (OTC) expectorants as people sought relief from respiratory symptoms associated with COVID-19."[3]

Key Takeaways

• The global guaifenesin market is expected to grow at a CAGR of around 3.1% from 2022 to 2027.
• The cough treatment drug segment is the fastest-growing segment.
• North America is the fastest-growing region for guaifenesin.
• The market is driven by increasing demand for cough and cold medications and advancements in healthcare infrastructure.
• Key players include Merck KGaA, Perrigo Company plc, and Sun Pharmaceutical Industries Ltd.

FAQs

What is the projected market size for guaifenesin by 2027?

The global guaifenesin market is forecasted to reach USD 95 million by 2027[1].

Which region is expected to be the fastest-growing market for guaifenesin?

North America is expected to be the fastest-growing region for guaifenesin, with a CAGR of around 4.5% during the forecast period[1].

What are the primary applications of guaifenesin?

Guaifenesin is primarily used in cough treatment drugs, chest congestion medications, and as an anesthetic in some cases[1].

How has the COVID-19 pandemic impacted the guaifenesin market?

The COVID-19 pandemic led to a surge in demand for expectorants like guaifenesin due to increased respiratory symptoms associated with the virus[3].

Who are the key players in the guaifenesin market?

Key players include Merck KGaA, Perrigo Company plc, Sun Pharmaceutical Industries Ltd, Johnson & Johnson Private Limited, and Sanofi[3].

Sources Cited

1. IndustryARC: Guaifenesin Market Size Report, 2022-2027.
2. CMS: Medicare Drug Price Negotiation Program.
3. Mordor Intelligence: Expectorant Drugs Market Size & Share Analysis.
4. Coherent Market Insights: Decongestant Market - Share, Size and Industry Analysis.